Menu Search
Equities

Burning Rock Biotech Ltd

6BU0:FRA

Burning Rock Biotech Ltd

Actions
  • Price (EUR)1.41
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-82.15%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 14:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.

  • Revenue in USD (TTM)70.45m
  • Net income in USD-78.32m
  • Incorporated2014
  • Employees786.00
  • Location
    Burning Rock Biotech LtdNo. 5 Xingdao Ring Road NorthInternational Bio IslandGUANGZHOU 510005ChinaCHN
  • Phone+86 18 501641666
  • Websitehttps://www.brbiotech.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.